For instance, when a germline TP53 pathogenic variant is detected in a patient with a breast cancer at 29 years of age without familial history, or in a 44-year breast cancer patient whose mother developed a sarcoma at 51, should we systematically offer pre-symptomatic testing in childhood since the first year of age? The gene discussed is TP53; the disease is breast carcinoma.